Comparison of triptorelin acetate vs triptorelin pamoate in the treatment of Central precocious puberty (CPP): a retrospective study

Abstract

The aim of this study is to compare the clinical and biochemical outcomes of triptorelin acetate (TPA) versus triptorelin pamoate (TPP) treatment in girls with central precocious puberty. A total of 60 patients with idiopathic CPP were retrospectively recruited. Thirty girls were treated with triptorelin acetate 3.75?mg/month (TPA group) and thirty girls in a second group received triptorelin pamoate 3.75?mg/4?weeks (TPP group). Patient follow-up at 12 and 24?months included GnRH Test at 12?months and baseline LH at 24?months. Patients were monitored with pelvic ultrasound, X-Ray of the hand and wrist and anthropometric evaluations. A total of 60/60 girls showed a good response to both formulations. Significant reductions in basal and LH peaks, estradiol values, breast pubertal stage, progression of bone age and growth velocity rate after 12?months treatment were obtained in both groups, demonstrating the equivalence of the two formulations in regulating the hypothalamic–pituitary-gonadal (HPG) axis. Triptorelin pamoate provided a more effective and significant reduction in LH peak after 12?months in comparison with triptorelin acetate more effective in reducing ovarian volume and endometrial thickness. Both formulations were equivalent, even though the LH peak was significantly lower in girls treated with triptorelin pamoate     

Cancer as an infectious disease: A different treatment alternative using a combination of tigecycline and pyrvinium pamoate – An example of breast cancer

BackgroundTigecycline is an antibiotic that well tolerated for treating complicated infections. It has received attention as an anti-cancer agent and expected to solve two major obstacles, sides effects that accompany chemotherapy and drug resistance, in the breast cancer treatment. However, previous studies reported that the levels in the blood are typically low of tigecycline, so higher doses are needed to treat cancer, that may increase the risk of side effects. To achieve better anti-cancer effects for tigecycline, we need to find a novel adjunct agent.MethodsIn this study, we used different concentration of pyrvinium pamoate combined with tigecycline to treat cell. And assess the effect of two drugs in inhibit cell proliferation, induce cell autophagy, or increase cell apoptosis to evaluate the consequent of combined therapy.ResultsWe observed that after the combined therapy, the cell cycle arrest at G1/s phase, the level of p21 increased, but decreased the levels of CDK2. Others, two drugs via different mechanisms to inhibit cancer cell proliferation and with selective cytotoxic to different cell lines. That could enhance the effect of breast cancer treatment.ConclusionCombining low dose of tigecycline use with pyrvinium pamoate is a novel approach for breast cancer treatment. Appropriate combined therapy in breast cancer is recommended to improve outcomes. Other problems like drug resistance occur in patients or the microbes surrounding breast tissues would confer susceptibility to cancers then influence the effectiveness of treatment, which could be improved through combined therapy.     

HPLC法测定双羟萘酸曲普瑞林中残留的三氟乙酸

目的建立新型混合模式色谱柱高效液相色谱法测定双羟萘酸曲普瑞林中三氟乙酸含量,并进行样品测定。方法采用Thermo Acclaim Mixed-Mode WAX-1(150 mm×4.6 mm,5μm)色谱柱;流动相:0.25 mol·L^-1磷酸二氢钠溶液(用6 mol·L^-1NaOH溶液调节p H值至6.0)∶乙腈(60:40);柱温:30℃;流速:1.0 mL·min^-1;检测波长:210 nm。结果空白溶剂及供试品中其他组分不干扰三氟乙酸测定,三氟乙酸在0.026~0.080 mg·mL^-1范围内线性关系良好,回归方程为:y=1104.3460x-0.6811,r=0.9998;定量下限为0.8μg;加样平均回收率为98.7%,RSD为1.1%;准确度高;具有良好的重复性;样品中未检出三氟乙酸。结论本方法准确、专属、耐用,可用于双羟萘酸曲普瑞林中三氟乙酸残留的测定。     

Bioequivalence of pyrantel pamoate dosage forms in healthy human subjects

Drugs that are largely restricted to the gastro-intestinal tract (GIT) for their therapeutic efficacy and that are not substantially absorbed into the body are usually inadequately studied in terms of systemic bioavailability. The possibility of systemic effects requires that bioavailabilities be studied to ensure against enhanced toxicity resulting from formulation differences. Pyrantel pamoate falls into this category. High-performance liquid chromatography was employed in this study to determine plasma levels of pyrantel in nine healthy human subjects after administration of tablet and suspension dosage forms. Mean peak plasma concentrations of 37.56 ± 9.37, 35.89 ± 8.94, and 36.22 ± 10.10 ng mL^?1 were obtained following administration of 750 mg pyrantel pamoate in three different formulations. The mean t_max values were 2.02 ± 0.12, 2.05 ± 0.356, and 2.05 ± 0.339 h respectively for the above dosage forms; the respective AUC_0–9 values were 81.01 ± 12.97, 94.59 ± 17.18, and 101.47 ± 19.59 h ng mL^?1. There was no statistically significant difference between the bioavailabilities of the dosage forms tested. Large inter-subject variations were observed. One subject experienced abdominal discomfort and one experienced dizziness. It was not possible to clearly correlate individual variations in absorption with the observed adverse effect because the number of incidents was low (two out of 27 treatments).     

江苏吴江市美洲钩虫种群调查及化疗研究

目的 开展有效化疗研究以控制吴江地区美洲钩虫病的流行。方法 通过对美洲钩虫感染性的流行病学调查和比较不同化疗方案，选择和推广应用有效化疗方法。结果 结果表明美洲钩虫感染占84．39％，混合感染占8．89％，美洲钩虫感染的平均虫负荷为2．82条，家庭聚集性K值为0．56，G值为325．44。在噻嘧啶、甲苯咪唑、阿苯达唑与甲苯咪唑伍用A组(3片)、甲苯咪唑与阿苯达唑联用B组(6片)、驱虫康I组、驱虫康Ⅱ组的阴转率分别为82．93％、95.74％、91．60%、95．74％、79．41％和88．71％。实验村的感染率下降91．13％，对照村的感染率下降13．37％，有显性差异。此外，防治试点的美洲钩虫感染率降至3．17％。结论 采用连续选择性化疗方法控制美洲钩虫可取得较为满意的近期和远期效果。值得在美洲钩虫流行区推广、应用。     

Follow-up study of patients treated with olanzapine pamoate in France in real-life treatment situation

Objective

To characterize patients treated with olanzapine pamoate in French centers and investigate the conditions of use of olanzapine pamoate in real-life treatment situation.

奥氮平双羟萘酸盐长效注射剂体外溶出度的测定

目的：建立奥氮平双羟萘酸盐长效注射剂的体外溶出度方法。方法：采用HPLC法测定奥氮平双羟萘酸盐长效注射剂的溶出度,采用浆法测定药物溶出度,溶出介质为0.5%十二烷基硫酸钠（SLS）模拟肌液（p H 7.0±0.05）,体积为500 ml,分别考察不同转速（25,50,75 r·min^-1）对自制制剂溶出行为的影响。结果：双羟萘酸在2.15-107.40 mg·L^-1（r=0.999 9）内,奥氮平在1.75-87.40 mg·L^-1（r=0.999 9）内浓度与峰面积呈良好的线性关系。奥氮平双羟萘酸盐的平均回收率为99.80%（RSD=0.55%,n=9）;自制制剂和原研制剂在溶出介质中溶出度相似因子f2为70.80。结论：溶出度测定方法能够有效控制该奥氮平双羟萘酸盐长效注射剂的产品质量。     

双羟萘酸噻嘧啶咀嚼片抗猪蛔虫的药理效应

目的 :研究双羟萘酸噻嘧啶咀嚼片抗猪蛔虫的药理效应。方法 :将双羟萘酸噻嘧啶咀嚼片、普通片与阿苯哒唑等抗寄生虫药对小猪人工感染蛔虫病理模型进行治疗 ,采用改良加藤氏厚涂片法比较上述各药治疗前后的 EPG(克粪便虫卵数 )和虫卵阴转率。结果 :双羟萘酸噻嘧啶咀嚼片与片剂一样在肠虫营养液中 ,显著引起蛔虫虫体僵硬 ,导致猪蛔虫头颈段活动停止。双羟萘酸噻嘧啶咀嚼片 8m g· kg- 1 和 10 mg· kg- 1 组对小猪感染蛔虫均具有非常显著的驱治效果 ,治疗后虫卵阴转率达 97.2 6 %和 10 0 % (88h)、97.5 1%和 10 0 % (186 h) ,与阴性对照组比较有显著性差异 ;10 m g· kg- 1 组虫卵阴转率及 EPG显著高于阿苯哒唑 (肠虫清 )对照组 ,P<0 .0 5。急性毒性试验结果表明小鼠腹腔注射试验药混悬液 L D50 为 12 7.74～ 16 7.86 m g· kg- 1 ;小鼠累积灌胃给予该药的最小致死量大于 8g· kg- 1。结论 :双羟萘酸噻嘧啶咀嚼片对小猪蛔虫感染具有显著的驱治效应